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Objectives: To estimate the 3-year budget impact of phased RF ablation system 
composed of three catheters -PVAC, MASC, MAAC- for the treatment of sympto-
matic, drug-refractory paroxysmal or persistent AF (PAF or CAF) patients in the 
Turkish setting. MethOds: Payer perspective is applied. Only direct costs are con-
sidered. Literature research is performed for epidemiologic data. Comparators are 
identified as “catheter ablation” technologies in the positive list: (1) magnetic (2) 
electric censored 3D-mapping catheter ablation, (3) pulmonary vein balloon cryo-
ablation (Medtronic ArcticFront). Device and procedure costs are derived from 
positive list prices For PVAC, MASC and MAAC offer prices are taken. Complication, 
re-hospitalization rates and length-of-stay are similar, thus related costs are 
ignored. AF-related-stroke costs are calculated based on comparative single-pro-
cedure success data, AF-related-stroke risk, and AF-related-stroke costs from a local 
expert panel. Market shares are derived from Medtronic sales data (May 2014-May 
2015) for cryo-ablation and AF market data. Two scenarios are run: (1) PVAC-only 
for PAF+CAF population, (2) MASC+MAAC combined with PVAC and/or ArcticFront 
for CAF-only. Results: Total AF population prediction is based on 50+ population. 
Prevalence data is derived from several global studies. The indicated population 
for catheter ablation is around 5,500 patients annually, the total catheter ablation 
market size corresponding to one-fourth of it; mainly due to insufficient number of 
accredited centers and physicians. 3-year budget impact per patient is 270TL, 276TL 
and 334TL in first and 268TL, 274TL and 334TL in second scenario. cOnclusiOns: 
If the limitations in quality-of-life, general health and related indirect costs are con-
sidered, the socioeconomic burden of disease would be significantly high. Indirect, 
long-term savings provided by significant shortening of procedure times with new 
technology are not included in the analysis, due to payer perspective. Considering 
these indirect costs and savings, the budget impact of new phased RF ablation 
system would be more positive.
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Objectives: To estimate the economic impact of the introduction of budesonide/
formoterol fixed-dose combination (FDC) with a new inhaler, Spiromax®, focusing 
on an increment of medication compliance due to an enhancement of the inhala-
tion technique for the treatment of Chronic Obstructive Pulmonary Disease (COPD) 
patients in five Spanish regions including Andalusia, Catalonia, Galicia, Madrid and 
Valencia. MethOds: A 4-year budget impact model was developed for the period 
2015─2018 for patients with COPD from the Spanish Healthcare System perspective. 
Budesonide/formoterol FDCs delivered by Turbuhaler® and Spiromax® inhalers 
were considered. All inputs were obtained from the published literature: regional 
data on COPD prevalence, non-compliance rates due to a poor inhaler technique, 
healthcare utilization related to non-compliance, medical resources associated with 
COPD management, budesonide/formoterol adverse event rates, and resource uti-
lization during hospitalization and at the emergency room. Based on the unit costs 
for drugs and medical resources, the annual treatment costs per patient associated 
to each inhaler and the annual cost per patient with an improvement in compliance 
were determined to estimate the overall budget impact. Results: The population 
with moderate to severe COPD treated with budesonide/formoterol FDCs in 2015 was 
estimated at 19,514, 20,016, 7,778, 21,289 and 9,936 patients in Andalusia, Catalonia, 
Galicia, Madrid and Valencia, respectively. Annual mean cost per patient was € 1,384 
before the introduction of Spiromax® and € 1,242 after its introduction and due to 
an improvement in medication compliance. Based on the forecast uptake of bude-
sonide/formoterol FDC delivered by Spiromax®, the model estimated the budget 
savings at € 2.34 million in Andalusia, € 2.23 millions in Catalonia, € 0.87 millions in 
Galicia, € 2.23 million in Madrid and € 0.77 million in Valencia, over the next four 
years. cOnclusiOns: The introduction of budesonide/formoterol FDC delivered 
by Spiromax® for the treatment of moderate and severe COPD patients is likely to 
represent savings for all five regions.
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Objectives: Heart failure (HF) is a very complex condition, with a wide range of 
unspecific clinical symptoms rendering its diagnosis very challenging, and associ-
ated co-morbidities contributing to increased expenditures. N-terminal pro-B-type 
natriuretic peptide (NTproBNP) levels increase in the blood when, in the course of 
developing acute HF, symptoms worsen. Therefore, NT-proBNP can be used as a spe-
cific diagnostic test of acute HF, whereas in patients with dyspnea it can further help 
to assess prognosis. The objective of the present study was to perform a cost and 
budget impact analysis of NT-proBNP testing. MethOds: A decision-analytic model 
formed the basis of the analysis. The model estimated the clinical consequences and 
outcomes and subsequent costs for patients presenting to the emergency department 
with dyspnea. Two diagnostic assessments were compared, NT-proBNP-supported 
diagnosis versus standard of care. The potential cost reduction, deriving from ade-
quate diagnosis and prognosis/monitoring, as well as the operating reductions (i.e 
hospitalizations) generated by NT-proBNP implementation were estimated. Clinical 
inputs derived from published literature and an expert panel provided insights into 
included in the study were with the mean age of 57 ± 14 of which 66.5% were male 
and 60.8% of the patients suffered from diabetes being a major cause for ESRD. 
Patients with age > 45, higher prevalence of diabetes, IDH, troponin T and other 
infection showed P value of 0.013, 0.002, 0.02, 0.05, 0.016 respectively, therefore 
predisposing these patient population at higher risk for SCD. Use of central venous 
catheter was associated with a 26.9 fold increase risk of death within first 90 days 
of initiation of HD. cOnclusiOns: Our study showed, type of vascular access for 
HD procedure, age, IHD, diabetes, LVH, LVSD, and EF are important factors for the 
survival of these patients and off the other factors found significantly associated to 
SCD were heart rate, breathlessness, other infections, catheter use, sodium levels 
and cholesterol levels.
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Objectives: Circulating tumour cells (CTCs) in the blood can give important infor-
mation about the prognosis and treatment options for cancer patients. Methods 
like cell-search are not sensitive enough because the blood samples are small (7,5 
mL). Currently a technique is developed which can separate CTCs from the whole 
blood and is called the CTC Trap. This study addresses the potential impact of imple-
menting the CTC Trap in addition to currently used imaging techniques in early 
staging of primary stage I-III breast cancer in women. MethOds: The early staging 
process has been identified using the Dutch breast cancer guideline. This process is 
displayed in a decision tree. Three points in this process have been identified as pos-
sible implementation options for the CTC Trap. A simulation model has been built 
in Excel to simulate the cost-effectiveness of implementing the CTC Trap at these 
three different points. Results: Potentially relevant points for the CTC trap are: 
1) following negative sentinel lymph node procedure to test for micro metastases, 
2) following negative result of initial MRI to test for (micro-) metastases, 3) follow-
ing negative results of further imaging. Usual care resulted in an average survival 
of 2,42 years, a 3-year survival of 93,71%, 1,51 QALYs and a cost of € 992,56. When 
implemented at all 3 implementation points simultaneously CTC Trap resulted in 
an average survival of 2,84 years, a 3-year survival of 97,46 %, 1,84 QALYS and a total 
cost of € 6.035,45. cOnclusiOns: CTCs clearly have the potential to improve overall 
survival. Use of CTCs can potentially improve survival with 0,42 years and improve 
QALYs with 0,34. Costs do increase at all options but from a health economic per-
spective it is most valuable to implement CTC Trap in option 1) following negative 
sentinel lymph node procedure to test for (micro-) metastases.
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Objectives: To assess the economic impact of the introduction of budesonide/
formoterol fixed-dose combination (FDC) with a new inhaler, Spiromax®, focusing 
on an increment of medication compliance due to an enhancement of the inhala-
tion technique for the treatment of moderate to severe asthmatics in five Spanish 
regions including Andalusia, Catalonia, Galicia, Madrid and Valencia. MethOds: 
A 4-year budget impact model was developed for the period 2015─2018 from the 
Spanish Healthcare System perspective. Budesonide/formoterol FDCs delivered 
by Turbuhaler® and Spiromax® were considered in this model. All inputs were 
obtained from the literature: regional data on asthma prevalence, non-compliance 
rates due to a poor inhaler technique, healthcare utilization related to non-com-
pliance, medical resources associated with asthma management, budesonide/for-
moterol adverse event rates, and resource utilization during hospitalization and 
at the emergency room. Based on the unit costs for drugs and medical resources, 
the annual treatment costs per patient associated to each inhaler and the annual 
cost per patient with an improvement in compliance were determined to estimate 
the overall budget impact. Results: The population with moderate to severe 
asthma treated with budesonide/formoterol FDCs in 2015 was estimated at 25,081, 
12,392, 16,097, 17,829 and 15,148 patients in Andalusia, Catalonia, Galicia, Madrid 
and Valencia, respectively. Annual mean cost per patient was estimated at € 1,619 
before the introduction of Spiromax®, and at € 1,481 after its introduction and due to 
an improvement in medication compliance. Based on the forecast uptake of bude-
sonide/formoterol FDC delivered by Spiromax®, the model estimated the budget 
savings at € 2.92 million in Andalusia, € 1.35 million in Catalonia, € 1.79 million in 
Galicia, € 1.83 million in Madrid and 1.30 € million in Valencia, over the next four 
years. cOnclusiOns: The introduction of budesonide/formoterol FDC delivered 
by Spiromax® for the treatment of moderate to severe asthma is likely to reduce 
the healthcare budget for five Spanish regions.
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